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Introduction. Adrenal metastasis of hepatocellular carcinoma (HCC) is a rare entity and can be treated by resection, local ablative
therapy, or systemic therapy. Unfortunately, data about treatment outcome, especially in liver transplant recipients, are rare.
Patients and Methods. From 2005 to 2015, 990 liver resections and 303 liver transplantations because of HCC were performed
at our clinic. We retrospectively analyzed treatment outcome of the patients with metachronous adrenal metastasis of HCC, who
received either resection, local ablation, or surveillance only. Results. 10 patients were identified (0.8%). 7 patients received liver
transplantation for primary HCC therapy, 3 liver resection, and 1 a local ablative therapy. 8 patients underwent adrenalectomy (one
via retroperitoneoscopy), one was treated with local ablation, and one had surveillance only. Seven out of eight patients had no
surgical complications and one experienced a pancreatic fistula, treated conservatively. 37.5% of the resected patients had recurrence
1 year after adrenalectomy and 75% after 2 years. The mean survival time after primary diagnosis of HCC was 96.6±22.4 months.
After adrenalectomy, the mean survival time was 112.4±25.2 months. The mean time until tumor recurrence was 13.2±3.8 in the
total cohort and 15.8±3.8 months in patients after adrenalectomy.The estimated overall survival after adrenalectomy was 77.2±17.4
months. Conclusion. Metachronous adrenal metastasis occured in less than 1% of HCC patients. Adrenalectomy is a safe procedure
and leads to acceptable survival rates even after liver transplantion.Therefore, it should be performed whenever the primary tumor
is well controlled and the patient is in adequate physical condition.
1. Introduction
Early detection using MRI and new treatment options like
laparoscopic surgery and local ablative therapy continuously
improved survival outcomes of hepatocellular carcinoma
(HCC) during the last decades. Therapeutic modalities for
the primarius range from surgical resection, systemic therapy,
and local ablative methods to liver transplantation. However,
HCC is still the second leading cause of cancer death
according to the worldwide statistical report of the World
Health Organization from 2012. Extrahepatic metastases of
HCC usually appear simultaneously with the primary tumor
but they can also occur during the further clinical course
with or without additional tumor recurrence [1]. Particularly
patients with advanced intrahepatic lesions (tumor stages
T3 and T4), vascular invasion, elevated tumor markers, and
viral hepatitis have a higher risk for extrahepatic metastases
from HCC with an incidence of 13.5%-42%. Furthermore,
extrahepatic metastases especially after liver transplantation
are more aggressive compared to those occurring in patients
without liver transplantation [2–6]. Generally, HCC dis-
seminates via the lymphatic or vascular pathway affecting
lymph nodes (33.8%) and most frequently the lung (53.8-
74.5%), followed by the bones (24.8-38.5%) and the adrenal
glands (8-19.1%) [1, 2, 4, 6–9]. Different therapeutic strategies
like local ablative methods and systemic therapy as well as
surgery have been considered for the therapy of adrenal
metastasis of HCC. Local treatment including transarterial
chemoembolization (TACE), percutaneous ethanol injection
(PEI), radiotherapy, and radiofrequency ablation provides
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survival rates of 42–42.5% at 1 year and a median survival
of 11.1–13.6months [9–13]. Patients with isolated extrahepatic
metastasis and preserved liver function may generally benefit
from a surgical resection [1, 7].
Previous reports of treatment outcome especially fol-
lowing liver transplantation are rare and mainly published
from Asian countries. Due to the small number of patients,
prospective studies comparing treatment outcome have not
been performed. Therefore, we analyzed our data from a
Western high volume liver center to evaluate incidence,
outcome, and survival of patients with adrenal metastasis of
HCC after liver resection and liver transplantation.
2. Patients and Methods
From January 2006 toDecember 2015 990 liver resections and
303 liver transplantations for HCC were performed at our
clinic. We detected ten patients with metachronous adrenal
metastases. Eight patients underwent adrenalectomy and one
patient was treated with local ablative therapy whereas one
adrenal metastasis remained untreated due to the patient’s
physical condition and tumor progression. Data was ret-
rospectively extracted from our digital patient data base.
Diagnosis of adrenalmetastasiswasmade by either computed
tomography or magnetic resonance imaging. Patients were
either grouped to those with or without liver transplantation
or those with or without adrenalectomy to analyze survival
and tumor recurrence seperately. The primary endpoint
of this study was survival after adrenalectomy; secondary
endpoints were the overall survival after primary diagnosis of
HCC and the time until tumor recurrence. Statistical analysis
was done using EXCEL (Version 15.21.1, 2016 Microsoft) with
the add-in XLSTAT (Version 2016.02.27941, Addinsoft, New
York, USA). The analysis was explorative. Kaplan-Meier-
analysis was used for survival rates.
3. Results
Thedemographic data are shown in Table 1. In eight patients,
an adrenalectomy was performed, one patient with bilateral
adrenal metastasis was treated with afterloading, and one
metastasis remained untreated due to severe tumor progress
and reduced physical condition of the patient. There were
seven male (70.0%) and three female patients (30.0%) in the
total cohort and six male (75.0%) and two female (25.0%)
patients in the adrenalectomy group (Table 1). The mean age
at the time of HCC diagnosis was 60.8±6.5 years (versus
60.9±6.5 years in the adrenalectomy group) and themean age
at the time of diagnosis of the adrenal metastasis was 63.9±7.1
years (versus 64.4±7.1 years in the adrenalectomy group).
The mean interval between detection of primary tumor
and adrenal metastasis was 30.8±6.5 months in the total
cohort, 37.0±8.2 months in patients after liver transplantation
(versus 16.3±3.3 in patients without liver transplantation),
and 34.0±7.7 months in the adrenalectomy group (versus
18.0±5 in nonadernalectomy group) (Table 1 and Figure 1).
50% of the patients showed BCLC stage B, three stage A,
and one C at the time of HCC diagnosis. 50% suffered
from a multifocal HCC with more than 3 tumor nodes;
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Figure 1: Display shows Kaplan-Meyer-Analysis of recurrence-free
rate after the primary diagnosis of HCC until the occurring diag-
nosis of an adrenal metastasis depending on the primary treatment
of the HCC either liver transplantation or resection/afterloading.
N=10.
three patients presented 1 and one patient 3 HCC nodes.
The average HCC tumor size was 42.0±23.0 in the total
cohort. The primary HCC was resected in three patients
(30%) and seven patients underwent liver transplantation
(70%). The only patient in whom the HCC in the liver was
treated with local ablative therapy developed bilateral adrenal
metastasis later on which were again treated locally (Table 1).
Metastases were located on the left side (n=5), on the right
side (n=4), or on both sides (n=1) (Table 1). The mean size of
the adrenal metastasis was 45.6+±21.4 mm (versus 45.1±21.6
mm in the adrenalectomy group, Table 1). Seven patients
were operated via an open approach and only one patient
underwent a retroperitoneoscopic procedure (Table 1). Seven
out of eight patients had no surgical complications after
adrenalectomy; one experienced a pancreatic fistula, which
was treated conservatively (Table 1).
The tumor recurrence rate one year after treatment
of the adrenal metastasis was 37.5% in the adrenalectomy
group (n=8, Table 1). After two years, six out of eight
patients (75%) after adrenalectomy showed tumor recurrence
at the following sites: intrahepatic recurrence (n=4), bone
metastases (n=3), brain metastasis (n=1), adrenal metastasis
on the contralateral side (n=2), and pulmonary recurrence
(n=2) after 28 months (Table 1). Only one patient developed
metastases at two extrehepatic sites and one patient an
intrehepatic and extrehepatic recurrence. The patient with
local ablative therapy for his adrenal metastasis experienced
tumor recurrence nine months after therapy (Table 1).
Themedian time until tumor recurrence (tumor progres-
sion free survival) was 12.5 (0-28) in the total cohort, 19 (4-
28) months in patients after adrenalectomy, and 4.5 (0-9)
months in no-adernalectomy group (Figure 2 and Table 1).
Themedian survival time after primary diagnosis ofHCCwas
82 (18-200) months (Figure 2 and Table 1). In patients after
adrenalectomy, the median survival time after primary diag-
nosis ofHCCwas 109.5 (17.5-200)months versu 31.5 (18-45) in
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male 7 (70.0%) 6 (75.0%) 1 (100%) 0
female 3 (30.0%) 2 (25.0%) 0 1 (100.0%)
Age at time of HCC (SD) [years] 60.8 (6.5) 60.9 (6.5) 54 67
Age at time of adrenal metastasis (SD) [years] 63.4 (7.1) 64.4 (7.1) 55 69
Interval since HCC (SD) [months] 30.8 (6.5) 34.0 (7.7) 13 23
37.0 (8.2) LTx
BCLC stage at time of diagnosis of HCC
A 3 (30.0%) 2 (25.0%) 1 (100%)
B 5 (50.0%) 5 (62.5%)
C 2 (20.0%) 1 (12.5%) 1 (100%)
Amount of HCC nodes at time of diagnosis
1 4 (40.0%) 2 (25.0%) 1 (100%) 1 (100%)
3 1 (10.0%) 1 (12.5%)
multifocal 5 (50.0%) 5 (62.5%)
Size of largest HCC node (SD) [mm] 42.0 (23.0) 47.0 (20.1) 7 10
Primary therapy of HCC
Liver resection 2 (30.0%) 1 (12.5%) 0 1 (100%)
Liver transplantation 7 (70.0%) 7 (87.5%) 0 0
Local ablative therapy 1 (10.0%) 0 1 (100%) 0
Side of adrenal metastasis
right 4 (30.0%) 3 (37.5%) 0 1 (100%)
left 5 (60.0%) 5 (62.5%) 0 0
bilateral 1 (10.0%) 0 1 (100%) 0
Size of adrenal metastasis (SD) [mm] 45.6 (21.4) 45.1 (21.6) 68 27
Type of adrenalectomy
open 7 (70.0%) 7 (87.5%) - -
retroperitoneoscopic 1 (10.0%) 1 (12.5%) - -
Surgical complications after adrenalectomy 1 (12.5%)
Recurrence rate after adrenal metastasis
After 1 year - 5 (37.5%) 1 (100%) -
After 2 years - 6 (75.0%) - -
Type of recurrence
Hepatic 6 (60.0%) 4 (50.0%) 1 (100%) 1 (100%)
Bone 3 (30.0%) 3 (37.5%) 0 0
Pulmonary 2 (20.0%) 2 (25.0%) 0 0
Brain 3 (30.0%) 1 (12.5%) 0 0
Adrenal contralateral 2 (20.0%) 2 (25.0%) 0 0
Time to progress [months] 12.5 (0-28) 19 (4-28)20 (4-28) LTx 0 9
Survival after HCC [months] 82 (17.5-200) 109.5 (17.5-200) 43 24
126 (17.5-200)LTx
Survival after adrenalectomy [months] - 69 (0.5-122) - -
81 (0.5-122) LTx
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Figure 2: Display shows Kaplan-Meyer-Analysis of estimated overall survival after the diagnosis of adrenal metastasis depending on the
treatment of the adrenal metastasis. N=10.
the group without adrenalectomy (Figure 2 and Table 1). The
median survival after adrenalectomy was 69 (0.5-122)months
and 89 (0.5-122) months after adrenalectomy following liver
transplantation (Table 1).
4. Discussion
The adrenal gland is a common site of metastatic HCC,
but still remaining a rare entity in clinical routine [14]. We
identified six patients after liver transplantation, three after
liver resection, and one after local therapy, who developed
adrenal metastasis at a mean of 30.8±19.4 months after
diagnosis of primary HCC. The timepoint of metastatic
development may depend on the initial treatment for HCC.
In previous series, adrenal metastasis occurs significantly
later after liver transplantation than after liver resection, a fact
that we could confirm in our patients [15]. One reason might
be that patients who were treated by liver transplantation
had a smaller primarius as they had to fullfill the Milan
criteria [16]. In contrary, most of our patients showed higher
BCLC stages and were transplanted beyond Milan criteria
following living donation. Furthermore, these patients were
on immunosuppression, which might facilitate the devel-
opment of malignancies. Previous investigations showed a
risk for HCC recurrence after liver transplantation of 25.0%
with most of the patients presenting extrahepatic recurrence
(80.0%). Particularly patients with a primary HCC beyond
Milan criteria or with macrovascular tumor invasion were
significantly associated with extrahepatic recurrence. But
among patients with primary HCC within the Milan criteria,
extrahepatic tumor recurrence was only associated in cases
of higher DNA-Index (DNA-index>1.5, p=0.013) [17]. In case
of HCC recurrence, metastases should be treated in the right
way, to improve patients’ survival.
Adrenalectomy was already performed for recurrence
of HCC in different settings after liver transplantation and
extensivemultivisceral resections or for palliativemetastasec-
tomy [18–20]. Minimal-invasive procedures were established
for small tumor size and certain risk factors and belong to
the standard today [21–25]. Most of our patients received a
primarily open surgical procedure, because of malignancy,
a larger size, and prior surgery with the risk for abdominal
adhesion. But we also owed a certain lack of experience
with those patients during the former time. In nowadays,
due to further development and experience with laparoscopic
adrenalectomies in benign dignities, it should be performed
whenever possible and retroperitoneoscopic adrenalectomy
may serve as a good alternative in case of severe adhe-
sion [26]. Alternatively to metastasectomy, a variation of
nonsurgical treatment options like PEI, TACE, radiation,
and radiofrequency ablation were also reported and recent
chemotherapeutic protocols achieved palliative control of
adrenal metastasis [27–31].
The first analysis and comparison of the different thera-
peutic modalities were published in France in 1998, including
13 patients [32]. The authors reported a longer survival
in the patients with surgical resection compared to those
with PEI and radiation, but two out of seven patients died
during the postoperative course. Therefore, the investigators
recommended surgical treatment for only selected patients
[33]. Other studies showed that adrenalectomy after curative
treatment for primary HCC could definitely improve survival
rates (68% at 1 year) in comparison to nonsurgical treatments
(42–42.5% at 1 year) [10–13, 33, 34]. Furthermore, depending
on the curative HCC treatment, Ha et al. could show espe-
cially longer recurrence-free and survival rates for patients
who initially received a liver transplantation compared to
those after curative liver resection [1]. According to that, our
patients after liver transplantation with adrenal recurrence
of a HCC also present a longer recurrence-free period after
treatment of the primarius and longer overall survival rates
after adrenalectomy compared to the group whose HCC was
primarily resected with no severe surgical complications.
Therefore, the aggressive treatment of HCC metastases in
the adrenal gland by adrenalectomy can improve long term
survival despite the risk for recurrence and perioperative
challenges after prior major abdominal surgery.
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5. Conclusion
Limitations of the present study are the small number of
patients and the retrospective design. However, our data are
consistent with the data from the few existing former studies.
Adrenalectomy is a safe treatment for adrenal metastases
of HCC even after liver transplantation and should be
performed whenever the primary tumor is well controlled
and when the patient is in adequate physical condition [10,
15, 35, 36].
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